期刊文献+

罗格列酮对脂多糖诱导的多器官功能障碍综合征大鼠保护作用的研究 被引量:8

Study of the protective effect of rosiglitazone on lipopolysaccharide-induced multiple organ dysfunction syndrome rats
下载PDF
导出
摘要 目的探讨罗格列酮(ROSI)对脂多糖(LPS)诱导的多器官功能障碍综合征(MODS)大鼠器官功能损伤的保护作用。方法健康雄性SD大鼠40只,随机分为四组(每组10只):①正常对照组;②LPS刺激组;③罗格列酮(ROSI)预处理组;④2-氯-5-硝基苯胺(GW9662)预处理组。在每组操作结束后4h取血用于主要器官生化指标的检测:肝功能、肾功能、心脏功能、胰腺功能。结果主要器官的生化指标在LPS组明显升高,与正常对照组比较差异有统计学意义(P<0.01)。ROSI预处理则大大减轻了指标的升高,与LPS组比较差异有统计学意义(P<0.01)。GW9662预处理则逆转了这种保护作用,器官功能指标低于LPS组,与LPS组比较差异无统计学意义(P>0.05)。结论罗格列酮预处理可减轻MODS大鼠器官功能损伤,为过氧化物酶体增殖物激活受体-γ(PPAR-γ)激动剂用于临床防治MODS提供了新的思路和依据。 Objective To investigate the protective effect of rosiglitazone on lipopolysaccharide - induced multiple organ dysfunction syndrome ( MODS) rats. Methods Forty male SD rats were randomly divided into four groups(n = 10 per group) : normal control group , lipopolysaccharide (LPS) group, ros- iglitazone ( ROSI ) pretreatment group, and PPAR -γ antagonist GW9662 pretreatment group. 4 hours after operation took blood to detect biochemical indicators of main organs: liver function(total bilirubin, alanine aminotransferase, aspartate aminotransferase ), renal function ( creatinine, blood urea nitrogen ), cardiac function ( creatine kinase, creatine kinase isozyme, lactate dehydrogenase ), pancreas function ( amylase). Results Biochemical indicators of main organs in LPS group were significantly higher than in vehicle control group (P 〈 0. 011. Biochemical indicators of main organs in ROSI group were significantly lower than in LPS group( P 〈0.01). In GW9662 group the biochemical indicators of main organs had no significant difference compared with LPS group ( P 〉 0. 05). Conclusion ROSI pretreatment may lessen the organ damage of MODS rats. The results supply new thinking and evidence with peroxisome proliferator activated receptor-γ excitomotor for MODS clinic precaution and treatmeat.
出处 《中国急救医学》 CAS CSCD 北大核心 2007年第6期550-552,共3页 Chinese Journal of Critical Care Medicine
基金 陕西省科技攻关课题(No.2006K14-G2)
关键词 多器官功能障碍综合征 脂多糖 罗格列酮 过氧化物酶体增殖物激活受体-Γ Multiple organ dysfunction syndrome Lipopolysaccharide Rosiglitazone Peroxisome proliferator activated receptor -γ
  • 相关文献

参考文献7

  • 1刘大为.危重病医学[M].北京:中国协和医科大学出版社,2003:51.
  • 2Moraes LA,Piqueras L.Peroxisome proliferator-activated receptors and inflammation[J].Pharmacol Ther,2006,110 (3):371-385.
  • 3Leesnitzer LM,Parks DJ,Bledsoe RK,et al.Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662[J].Biochemistry,2002,41 (21):6640 -6650.
  • 4Cuzzocrea S,Pisano B,Dugo L,et al.Rosiglitazone,a ligand of the peroxisome proliferator-activated receptor-γ,reduces acute inflammation[J].Eur J Pharmacol,2004,483(1):79-93.
  • 5Zlingarelli B,Cook JA.Peroxisome proliferator-activated receptorgamma is a new therapeutic target in sepsis and inflammation[J].Shock,2005,23 (5):393-399.
  • 6Ruan QR,Zhang WJ,Hufnagl P,et al.Anisodamine counteracts lipopolysaccharide-induced tissue factor and plasminogen activator inhibitor-1 expression in human endothelial cells:contribution of the NF-kappa B pathway[J].J Vasc Res,2001,38(1):13-19.
  • 7Paterson RL,Galley HF Dhillon JK,et al.Increased nuclear factor kappa B activation in critically ill patients who die[J].Crit Care Med,2000,28(4):1047-1051.

共引文献10

同被引文献76

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部